



Metabolic Mechanism and Physiological Role of Glycerol 3-Phosphate in *Pseudomonas aeruginosa* PAO1

Yidong Liu,^a Wenxuan Sun,^a Liting Ma,^a Rong Xu,^a Chunyu Yang,^a Ping Xu,^{b,c} Cuiqing Ma,^a Chao Gao^a

^aState Key Laboratory of Microbial Technology, Shandong University, Qingdao, People's Republic of China

^bState Key Laboratory of Microbial Metabolism, Shanghai Jiao Tong University, Shanghai, People's Republic of China

^cSchool of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, People's Republic of China

ABSTRACT *Pseudomonas aeruginosa* is an important opportunistic pathogen that is lethal to cystic fibrosis (CF) patients. Glycerol generated during the degradation of phosphatidylcholine, the major lung surfactant in CF patients, could be utilized by *P. aeruginosa*. Previous studies have indicated that metabolism of glycerol by this bacterium contributes to its adaptation to and persistence in the CF lung environment. Here, we investigated the metabolic mechanisms of glycerol and its important metabolic intermediate glycerol 3-phosphate (G3P) in *P. aeruginosa* PAO1. We found that G3P homeostasis plays an important role in the growth and virulence factor production of *P. aeruginosa* PAO1. The G3P accumulation caused by the mutation of G3P dehydrogenase (GlpD) and exogenous glycerol led to impaired growth and reductions in pyocyanin synthesis, motilities, tolerance to oxidative stress, and resistance to kanamycin. Transcriptomic analysis indicates that the growth retardation caused by G3P stress is associated with reduced glycolysis and adenosine triphosphate (ATP) generation. Furthermore, two haloacid dehalogenase-like phosphatases (PA0562 and PA3172) that play roles in the dephosphorylation of G3P in strain PAO1 were identified, and their enzymatic properties were characterized. Our findings reveal the importance of G3P homeostasis and indicate that GlpD, the key enzyme for G3P catabolism, is a potential therapeutic target for the prevention and treatment of infections by this pathogen.

IMPORTANCE In view of the intrinsic resistance of *Pseudomonas aeruginosa* to antibiotics and its potential to acquire resistance to current antibiotics, there is an urgent need to develop novel therapeutic options for the treatment of infections caused by this bacterium. Bacterial metabolic pathways have recently become a focus of interest as potential targets for the development of new antibiotics. In this study, we describe the mechanism of glycerol utilization in *P. aeruginosa* PAO1, which is an available carbon source in the lung environment. Our results reveal that the homeostasis of glycerol 3-phosphate (G3P), a pivotal intermediate in glycerol catabolism, is important for the growth and virulence factor production of *P. aeruginosa* PAO1. The mutation of G3P dehydrogenase (GlpD) and the addition of glycerol were found to reduce the tolerance of *P. aeruginosa* PAO1 to oxidative stress and to kanamycin. The findings highlight the importance of G3P homeostasis and suggest that GlpD is a potential drug target for the treatment of *P. aeruginosa* infections.

KEYWORDS *Pseudomonas aeruginosa*, glycerol, glycerol 3-phosphate, glycerol 3-phosphate dehydrogenase, glycerol 3-phosphate phosphatase

Pseudomonas aeruginosa is an opportunistic Gram-negative pathogen that infects a broad range of hosts, including plants, animals, and humans (1). It is recognized as the primary cause of morbidity and mortality in patients with cystic fibrosis (CF) (2). The considerable metabolic versatility of *P. aeruginosa* enables it to adapt to and persist in the CF lung environment (3). Phosphatidylcholine, the major lung surfactant in CF patients, can be cleaved into phosphorylcholine, fatty acids, and glycerol by

Editor Sang Yup Lee, Korea Advanced Institute of Science and Technology

Copyright © 2022 Liu et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Chao Gao, jieerbu@sdu.edu.cn.

The authors declare no conflict of interest.

This article is a direct contribution from Ping Xu, a Fellow of the American Academy of Microbiology, who arranged for and secured reviews by Zhao-Qing Luo, Department of Biological Sciences, Purdue University; Lefu Lan, Shanghai Institute of Materia Medica; Xihui Shen, State Key Lab Crop Stress Biology for Arid Areas, College of Life Sciences, Northwest A&F University; and Haihua Liang, Southern University of Science and Technology.

Received 18 September 2022

Accepted 20 September 2022

Published 11 October 2022

P. aeruginosa-produced phospholipase C and lipases (4). Importantly, it has been demonstrated that glycerol metabolic genes are upregulated in *P. aeruginosa* isolates obtained from patients with CF (4), which indicates that the metabolism of glycerol may contribute to the persistence of *P. aeruginosa* in the CF lung environment.

During aerobic microbial metabolism, glycerol is initially phosphorylated to glycerol 3-phosphate (G3P) by the adenosine triphosphate (ATP)-dependent glycerol kinase (GlpK). Subsequently, G3P dehydrogenase (GlpD) catalyzes the dehydrogenation of G3P to yield dihydroxyacetone phosphate (DHAP), which undergoes isomerization to glyceraldehyde-3-phosphate prior to entering the gluconeogenic or glycolytic pathway (5, 6). In addition, G3P can be acylated by acyl-CoA to initiate the biosynthesis of membrane lipids (7) and storage lipids (8) in microbes. However, the generation of excessive G3P may also be toxic, and indeed, as early as 1965, the accumulation of G3P was reported to cause the growth stasis of *Escherichia coli* (9). In some glycerol-producing microbes, such as *Saccharomyces cerevisiae* (10) and *Corynebacterium glutamicum* (11), glycerol 3-phosphate phosphatase (G3PP), which dephosphorylates G3P to yield glycerol, has been identified.

Given its impressive intrinsic resistance, potential to acquire resistance to current antibiotics, and deployment of an arsenal of virulence factors, the prevention of *P. aeruginosa* infections presents a considerable challenge in health care settings (2, 12). Accordingly, there exists an urgent need to develop new therapeutic strategies by which to combat multidrug-resistant *P. aeruginosa*. Many recent studies have indicated that there is a close association between physiological metabolism and bacterial sensitivity to antibiotics and their virulence (13–15). Thus, it is plausible that inhibiting specific enzymes in bacterial metabolic pathways may also contribute to the control of drug-resistant bacteria. For example, Puckett et al. (16) have demonstrated that deletion of malate synthase induces the accumulation of the toxic metabolite glyoxylate during the utilization of host fatty acids by *Mycobacterium tuberculosis*, thereby reducing its growth and persistence in acute and chronic mouse infections. Accordingly, malate synthase was proposed as a potential drug target in cases of *M. tuberculosis* infections. Similarly, promysalin, which has recently been identified as an inhibitor of the succinate dehydrogenase of *P. aeruginosa*, is considered to be a promising “narrow-spectrum” antibiotic for the treatment of *P. aeruginosa* infections (17). Given the putative role of glycerol metabolism in the adaptation of *P. aeruginosa* to the CF lung environment, we speculate that the proteins associated with the metabolism of glycerol or with its phosphorylated product G3P may serve as antibiotic targets for the treatment of *P. aeruginosa* infections.

In the present study, we seek to elucidate the mechanisms underlying the synthesis, degradation, and transport of G3P in *P. aeruginosa* type strain PAO1. We demonstrate the importance of G3P homeostasis for its growth and virulence factor production. The decreased transcription of genes in the Entner-Doudoroff (ED) pathway and impaired ATP production may be associated with the growth defects induced by G3P accumulation. In addition, we identify PA0562 and PA3172 as the G3PPs that mediate the dephosphorylation of this toxic metabolite. These findings indicate that the G3P catabolic enzyme GlpD could serve as a potential therapeutic target by which to control *P. aeruginosa* infections.

RESULTS

Identification of G3P metabolism-related genes in *P. aeruginosa* PAO1. In *P. aeruginosa* PAO1, the genes involved in glycerol metabolism, including *glpF* (glycerol facilitator, PA3581), *glpK* (glycerol kinase, PA3582), *glpR* (glycerol regulon repressor, PA3583), and *glpD* (G3P dehydrogenase, PA3584), are arranged in a genomic cluster. These genes have provisionally been identified or annotated in previous studies (1, 18–20). In the present study, we initially examined their roles in the metabolism of glycerol by *P. aeruginosa* PAO1. Neither the $\Delta glpD$ nor the $\Delta glpK$ mutants grew in minimal salt medium (MSM) containing 20 mM glycerol as the sole carbon source (Fig. 1A). The loss of *glpF* was found to affect the growth and glycerol utilization of *P. aeruginosa* PAO1 ($\Delta glpF$) only at a low glycerol concentration (2 mM) (Fig. S1A and B). Conversely, the knockout of *glpR* enabled




FIG 1 Synthesis, degradation, and transport mechanisms of glycerol 3-phosphate (G3P) in *P. aeruginosa* PAO1. (A) Growth of *P. aeruginosa* PAO1 (black line), $\Delta glpK$ (blue line), and $\Delta glpD$ (pink line) with 20 mM glycerol as the sole carbon source. (B) Growth of *P. aeruginosa* PAO1 (black line) and $\Delta gpsA$ (red line) with 20 mM succinate (Suc) or 20 mM succinate and 20 mM glycerol (Suc + Gly) as the carbon sources. (C) Growth of *P. aeruginosa* PAO1 (black line), $\Delta glpD$ (pink line), and $\Delta glpT$ (green line) with 10 mM G3P as the sole carbon source. (D) Schematic representation of G3P metabolism in *P. aeruginosa* PAO1. G3P can be imported from the extracellular environment, derived from glycerol phosphorylation, or synthesized via the reduction of dihydroxyacetone phosphate. Then, G3P will be fluxed into membrane and storage lipid biosynthesis or into the central carbon metabolism. GlpR represses the expression of glycerol metabolic regulon and uses G3P as its effector. All data shown are the average values of three independent experiments \pm the standard deviation (SD).

P. aeruginosa PAO1 ($\Delta glpR$) to grow more rapidly than the wild-type strain when glycerol was the sole carbon source (Fig. S1C).

We established that GlpR represses the utilization of glycerol by *P. aeruginosa* PAO1 by binding to the promoters of *glpFK* and *glpD* (Fig. S1D and E), as has been observed in *P. putida* KT2440 (21). Interestingly, it uses G3P rather than glycerol as the effector to induce the expression of *glpFK* and *glpD* (Fig. S1D and E). We also examined the metabolism of G3P by *P. aeruginosa* PAO1. In addition to the phosphorylation of glycerol, G3P can be generated via DHAP reduction. The biosynthetic G3P dehydrogenase (GpsA), which catalyzes this reduction for *de novo* G3P biosynthesis *in vivo*, has previously been identified in *E. coli* (22, 23). The orthologous protein of GpsA has also been annotated in the *P. aeruginosa* PAO1 genome. It was found that the knockout of *gpsA* (*PA1614*) results in a G3P auxotrophic phenotype, which could be complemented by the provision of exogenous glycerol (Fig. 1B; Fig. S1F). It was also found that *P. aeruginosa* PAO1 could grow in MSM containing 10 mM G3P as the sole carbon source (Fig. 1C). The G3P transporter (GlpT) has previously been identified in *P. aeruginosa* (24). Furthermore, the knockout of *glpT* (*PA5235*) or *glpD* impaired the ability of *P. aeruginosa* PAO1 to utilize G3P (Fig. 1C), thereby demonstrating the role of GlpT in G3P transport and the role of GlpD in G3P catabolism.




FIG 2 Pyocyanin, exopolysaccharides, twitching motility, and oxidative stress tolerance of *P. aeruginosa* PAO1 and its derivatives. (A) Spectrophotometric quantitation of pyocyanin produced by *P. aeruginosa* PAO1 and its derivatives at stationary-phase. Pyocyanin production was also indicated by photographs of the acidified extracts of the cultures of *P. aeruginosa* PAO1 and its derivatives with chloroform. The pink color is proportional to the amount of pyocyanin. (B) Diameters of subsurface twitching motility zones. Twitching motility was also indicated by photographs of *P. aeruginosa* PAO1 and its derivatives on 1% agar plates. (C) Colony morphology on Congo red plates. (D) Diameters and photographs of bacteriostatic zones generated by 30% (wt/wt) H_2O_2 . All strains were grown with Luria-Bertani (LB) medium. All data shown are the average values of three independent experiments \pm SD. Two-tailed *P* values were determined using unpaired *t* tests. **, *P* < 0.01; ***, *P* < 0.001; ****, *P* < 0.0001; ns, no significant difference (*P* \geq 0.05).

From these results, we can summarize the synthesis, degradation, and transport mechanisms of G3P in *P. aeruginosa* PAO1. As shown in Fig. 1D, the production of G3P can be achieved via the phosphorylation of glycerol by GlpK and the reduction of DHAP by GpsA, respectively. In addition, extracellular G3P can enter cells via GlpT-mediated transport, whereas the catabolism of G3P depends on GlpD-catalyzed dehydrogenation to produce DHAP.

Mutation of *glpD* affects production of pyocyanin and exopolysaccharides, twitching motility, and oxidative stress tolerance. GlpR uses G3P instead of glycerol as its effector to regulate glycerol and G3P catabolism (Fig. S1D and E), thereby implying that intracellular G3P, rather than glycerol, is involved in maintaining the cellular homeostasis of *P. aeruginosa* PAO1. To characterize the G3P metabolism of *P. aeruginosa* PAO1, we cultured the wild-type strain and mutants related to G3P metabolism in Luria-Bertani (LB) medium. Then, the pyocyanin production, twitching motility, exopolysaccharide generation, and oxidative stress tolerance of *P. aeruginosa* PAO1, $\Delta glpD$, $\Delta glpK$, and $\Delta gpsA$ were assayed. Pyocyanin is a vital virulence factor produced by *P. aeruginosa* (3). As shown in Fig. 2A, there was a clear reduction in the pyocyanin production of the $\Delta glpD$ mutant, whereas we detected a significant increase in that of $\Delta gpsA$. The type IV pili-mediated twitching motility of *P. aeruginosa* is necessary for bacterial adhesion and for the initiation of infection in CF patients (25). As shown in Fig. 2B, the knockout of either *glpD* or *gpsA* resulted in a reduction in twitching




FIG 3 G3P accumulation inhibits the growth of *P. aeruginosa* PAO1. (A) Growth of *P. aeruginosa* PAO1 with 20 mM succinate and 20 mM glycerol as the carbon sources. The level of growth (black line) and consumption of succinate (orange line) and glycerol (blue line) were measured. (B) Log-phase growth rate (R) of *P. aeruginosa* PAO1, $\Delta glpD$, and $\Delta glpD\Delta glpK$ with 20 mM succinate (black columns) or 20 mM succinate and 20 mM glycerol (red columns) as the carbon sources. (C) Log-phase growth rate (R) of *P. aeruginosa* PAO1 (black column) and $\Delta glpD$ (orange column) with 20 mM succinate and different concentrations of glycerol as the carbon sources. (D) Log-phase growth rate (R) of *P. aeruginosa* PAO1 and $\Delta glpD$ with 20 mM succinate (black columns) or 20 mM succinate and 10 mM G3P (blue columns) as the carbon sources. (E and F) Intracellular (E) and extracellular (F) G3P concentrations of *P. aeruginosa* PAO1 and $\Delta glpD$ grown with 40 mM succinate before and after the addition of 20 mM glycerol. All data shown are the average values of three independent experiments \pm SD. Two-tailed P values were determined using unpaired t tests. **, $P < 0.01$; ***, $P < 0.001$; ****, $P < 0.0001$; ns, no significant difference ($P \geq 0.05$).

motility. The cells of *P. aeruginosa* often reside in exopolysaccharide-enclosed biofilms, which are assumed to confer enhanced resistance to antibiotics (26). To quantify the exopolysaccharides produced by *P. aeruginosa* PAO1 and its G3P metabolism-related mutants, we performed a Congo red binding assay (27). The results showed that fewer exopolysaccharides were produced by the $\Delta glpD$ mutant (Fig. 2C). Hydrogen peroxide (H_2O_2) is an oxidizing agent produced by the host immune system (28). H_2O_2 sensitivity assays revealed that the knockout of *glpD* reduced the tolerance of *P. aeruginosa* PAO1 to oxidative stress (Fig. 2D).

G3P accumulation leads to reductions in growth, pyocyanin production, motilities, and oxidative stress tolerance, as well as antibiotic susceptibility. *P. aeruginosa* can cleave the phosphatidylcholine in CF airways, thereby yielding phosphorylcholine, fatty acids, and glycerol (4). In the present study, we observed that *P. aeruginosa* PAO1 cointilizes glycerol and other favorable carbon sources, such as succinate or glucose (Fig. 3A; Fig. S2A). $\Delta glpD$ was cultured in MSM containing 20 mM succinate or glucose and 20 mM glycerol. As shown in Fig. 3B; Fig. S2B, exogenous glycerol inhibited the growth of $\Delta glpD$, with this inhibitory effect being shown to be dose-dependent (Fig. 3C; Fig. S2C). Exogenous G3P also inhibited the growth of the $\Delta glpD$ mutant (Fig. 3D). In addition, the knockout of *glpK*, which is responsible for glycerol phosphorylation, was found to partially alleviate the inhibitory effect of glycerol on $\Delta glpD$ (Fig. 3B; Fig. S2B), thereby indicating a possible correlation between the inhibition of growth caused by a *GlpD* deficiency and the accumulation of G3P.

The wild-type strain and the $\Delta glpD$ mutant were cultured to the logarithmic phase of growth in MSM containing 40 mM succinate as the sole carbon source, after which 20 mM glycerol was added and the concentrations of intracellular and extracellular G3P were determined. As shown in Fig. 3E and F, there were significant accumulations




FIG 4 Effects of G3P stress on the pyocyanin production, motilities, oxidative stress tolerance, and antibiotic resistance of *P. aeruginosa* PAO1. (A to D) Spectrophotometric quantitation of pyocyanin (A). Diameters of subsurface twitching motility zones on 1% agar plates (B). Diameters of surface swimming motility zones on 0.3% agar plates (C). Diameters of bacteriostatic zones generated by 30% (wt/wt) H_2O_2 (D). WT(EV), *P. aeruginosa* PAO1 complemented with the empty vector pBBRMCS-5; $\Delta glpD$ (EV), $\Delta glpD$ complemented with the empty vector pBBRMCS-5; $\Delta glpD$ (*glpD'*), $\Delta glpD$ complemented with pBBR-*glpD*. (E) Kanamycin sensitivity assay. All strains were grown with 20 mM succinate (Suc) or 20 mM succinate and 20 mM glycerol (Suc + Gly) as the carbon sources. All data shown are the average values of three independent experiments \pm SD. Two-tailed *P* values were determined using unpaired *t* tests. **, *P* < 0.01; ***, *P* < 0.001; ****, *P* < 0.0001; ns, no significant difference (*P* \geq 0.05).

of both intracellular and extracellular G3P in $\Delta glpD$, whereas we detected no apparent accumulation of G3P in the wild-type strain. Similar results were obtained when $\Delta glpD$ was cultured in MSM containing glucose as the sole carbon source (Fig. S2D and E).

We also examined the pyocyanin production, twitching and swimming motilities, oxidative stress tolerance, and antibiotic resistance of the $\Delta glpD$ mutant under conditions with exogenous glycerol. As shown in Fig. 4A and Fig. S3A, exogenously supplied glycerol completely prevented the production of pyocyanin by $\Delta glpD$. We also observed reductions in




FIG 5 Transcriptomic response of *P. aeruginosa* PAO1 to G3P stress. The mutation of GlpD blocks glycerol catabolism and results in the accumulation of G3P. Transcriptomic analysis revealed that genes relating to type IVa pili biosynthesis, antioxidants, sulfur assimilation, and [Fe-S] biosynthesis were repressed by G3P accumulation, resulting in reduced twitching motility, oxidative stress tolerance, and antibiotic resistance as well as the impaired functioning of [Fe-S]-containing enzymes. Anthranilate degradation was activated under G3P stress, which may compete with pyocyanin biosynthesis for the common precursor chorismate. Details about the displayed genes can be found in Table S1.

the twitching and swimming motilities of $\Delta glpD$ in the presence of glycerol (Fig. 4B and C; Fig. S3B and C). Exogenous glycerol markedly increased the susceptibility of $\Delta glpD$ to H_2O_2 (Fig. 4D; Fig. S3D) and kanamycin (Fig. 4E). Furthermore, we found that the pyocyanin generation, motilities, and oxidative stress tolerance of the complementary strain $\Delta glpD(glpD')$ recovered to various degrees (Fig. 4A to D; Fig. S3). Thus, these results indicate that the accumulation of G3P will lead to reductions in the pyocyanin production, motilities, and tolerances of *P. aeruginosa* PAO1.

Transcriptomic response of *P. aeruginosa* PAO1 to G3P stress. We adopted a transcriptomic approach to examine the changes in G3P-induced gene expression in *P. aeruginosa* PAO1. Having cultured $\Delta glpD$ in MSM containing 40 mM succinate as the carbon source to an optical density at 600 nm (OD_{600nm}) of 1, we added 20 mM glycerol to induce G3P accumulation. Cells treated with exogenous glycerol were subjected to transcriptomic analysis and compared to untreated cells.

P. aeruginosa is characterized by the production of two major subfamilies of type IV pili, namely, type IVa pili and type IVb pili (29, 30). Type IVa pili are typically responsible for twitching motility, which plays important roles in the adherence of bacteria to surfaces and in the migration of bacteria toward attractants (29). Accordingly, we speculate that a reduction in the expression of genes related to type IVa pili biosynthesis may account for the impaired twitching motility observed in the $\Delta glpD$ mutant in response to an accumulation of G3P (Fig. 5; Table S1).

OxyR positively regulates a series of defensive genes against oxidative stress (31), and 1-cys peroxiredoxin LsfA is similarly involved in protecting cells from superoxide-induced stress (32). Thus, it is conceivable that the significantly reduced levels of *oxyR* and *LsfA* mRNA observed in response to an accumulation of G3P may account for the increased susceptibility of *P. aeruginosa* to oxidative stress under these conditions (Fig. 5; Table S1). In bacteria, sulfonates and sulfate esters are considered to serve as the major sources of sulfur for cysteine and methionine biosynthesis (33). In *P. aeruginosa*, the H_2S generated from cysteine is required for defense against antibiotics (34). Most genes associated with sulfate transport (*cysAWTP*) and metabolism (*cysND*),

taurine transport (*tauBC*), and alkanesulfonate metabolism (*ssuABCDE*) have been shown to be downregulated (33) (Table S1), indicating that the attenuated assimilation of sulfur might affect the resistance of *P. aeruginosa* to antibiotics under conditions of G3P stress (Fig. 5). Similarly, the genes associated with iron-sulfur cluster ([Fe-S]) biosynthesis (*iscRSUA-hscBA-fdx2*) were also significantly downregulated in the Δ *glpD* mutant in response to the addition of glycerol (Table S1), which may influence numerous physiological processes involving [Fe-S]-containing enzymes (35) (Fig. 5).

Notably, however, we found that the genes involved in the synthesis of pyocyanin (*phz* operon) were upregulated (Table S1), which appears to be inconsistent with the observed reduction in pyocyanin production in cells subjected to G3P stress (Fig. 4A). Chorismate is the precursor of pyocyanin biosynthesis catalyzed by the enzymes encoded by the *phz* operon (36). It can also be converted to anthranilate and is thereafter degraded to catechol by *antABC*-encoded anthranilate dioxygenase before it eventually enters the tricarboxylic acid (TCA) cycle (Fig. S4). The transcriptomic analysis revealed that *antABC* was more highly upregulated than was the *phz* operon (Table S1), which may thus divert the flux of chorismate into anthranilate degradation and thereby result in a reduction in pyocyanin production (Fig. 5).

ATP generation is reduced in *P. aeruginosa* PAO1 under G3P stress. *P. aeruginosa* employs the ED pathway for glycolysis (37), the participating genes of which are arranged in two regulons. One of these regulons consists of *zwf* (encoding glucose-6-phosphate 1-dehydrogenase), *pgl* (encoding 6-phosphogluconolactonase), and *eda* (encoding 2-keto-3-deoxy-6-phosphogluconate aldolase), whereas the other consists of *edd* (encoding 6-phosphogluconate dehydratase) and *gapA* (encoding glyceraldehyde-3-phosphate dehydrogenase). Transcriptome sequencing results revealed a clear downregulation of these ED pathway regulons in Δ *glpD* in response to G3P accumulation (Fig. 6A; Table S1).

Pyruvate dehydrogenase catalyzes the oxidative decarboxylation of pyruvate to acetyl-CoA (Fig. 6A). In the present study, we detected a downregulation of the expression of the pyruvate dehydrogenase complex genes *aceE* and *aceF* (38) in Δ *glpD* following the addition of glycerol (Table S1). We also detected a reduction in the transcription of *bo₃* quinol oxidase (encoded by *cyoABCDE*) of the electron transport chain under aerobic respiration (39), whereas the transcription of multiple genes involved in nitrate-dependent anaerobic respiration (*narK1K2GHJI*, *nirSMCFDLGHJEN*, and *nosRZDFYL*) (40) was increased under G3P accumulation (Table S1). These findings indicate that G3P accumulation has an inhibitory effect on aerobic respiration. This G3P-induced downregulation of glucose metabolism in aerobic respiration would presumably result in a reduced ATP pool. Thus, we also assayed the levels of ATP in *P. aeruginosa* PAO1 and Δ *glpD* before and after the addition of glycerol. As expected, we detected a reduction in ATP levels in Δ *glpD* under G3P accumulation (Fig. 6B and C).

Identification of putative G3PPs in *P. aeruginosa* PAO1. Phosphatases that convert G3P into glycerol have been identified in many organisms (10, 11). We performed a position-specific-iterated BLAST search using the amino acid sequence of *S. cerevisiae* G3PP RHR2 (NP_012211.2) as a query. Three homologous proteins belonging to the haloacid dehalogenase (HAD)-like hydrolases were found in *P. aeruginosa* PAO1, including PA0562, PA3172, and PA2067, which share 20%, 23%, and 22% identities with *S. cerevisiae* G3PP RHR2, respectively (Fig. S5). According to the annotations in the National Center for Biotechnology Information (NCBI) database, PA0562 and PA3172 may have phosphatase activities, while PA2067 may be a β -phosphoglucomutase YcjJ. By overexpressing these three candidate G3PPs in Δ *glpD*, we found that only overexpressed PA0562 and PA3172 alleviated the effects of G3P stress and resulted in an increase in the log-phase growth rate of Δ *glpD* (Fig. 7A and B; Fig. S6). Consistently, the knockout of PA0562 and PA3172 in Δ *glpD* had the effect of enhancing the inhibition of growth attributable to accumulated G3P (Fig. 7C and D). These findings imply that PA0562 and PA3172 are G3PPs of *P. aeruginosa* PAO1.

Then, the enzymes PA0562 and PA3172 were overexpressed in *E. coli* BL21(DE3) and purified through nickel affinity chromatography. The kinetic parameters of PA0562 and




FIG 6 G3P accumulation inhibits the expression of genes in the Entner-Doudoroff (ED) pathway and adenosine triphosphate (ATP) production of *P. aeruginosa* PAO1. (A) Transcriptional response of genes in the ED pathway to G3P stress in *P. aeruginosa* PAO1. Genes that are significantly downregulated are labeled in green. (B and C) ATP detection of *P. aeruginosa* PAO1 and $\Delta glpD$ grown with 40 mM succinate (B) or 40 mM glucose (C) before and after the addition of 20 mM glycerol. All data shown are the average values of three independent experiments \pm SD. Two-tailed *P* values were determined using unpaired *t* tests. ***, *P* < 0.001; ****, *P* < 0.0001; ns, no significant difference (*P* \geq 0.05).

PA3172 toward G3P were determined (Fig. 8A and B). The apparent K_m values of PA0562 and PA3172 toward G3P were 8.937 ± 1.350 mM and 5.634 ± 0.209 mM, respectively. The corresponding V_{max} values were estimated to be 11.840 ± 0.976 U·mg⁻¹ and 4.014 ± 0.068 U·mg⁻¹, respectively.

PA0562 and PA3172 belong to the HAD-like phosphatases (41). The members of these phosphatases in *E. coli* (42) and *P. fluorescens* (43) have been demonstrated to have broad substrate spectra. In contrast, it has been found that G3PPs from glycerol-overproducing microbes, such as *S. cerevisiae* (44) and *C. glutamicum* (11), exhibit high substrate specificity and catalytic efficiency. From the substrate profiles of PA0562 and PA3172, we established that, in addition to G3P, PA0562 can catalyze the dephosphorylation of glucose-6-phosphate, ribose-5-phosphate, and fructose-6-phosphate, with the highest activity being detected when glucose-6-phosphate was used as a substrate (Fig. 8C). PA3172 also had a relatively broad substrate spectrum, with its activities toward 2-phosphoglycerate, 3-phosphoglycerate, and 6-phosphogluconate all being lower than its activity toward G3P (Fig. 8D).

DISCUSSION

P. aeruginosa is a major human nosocomial pathogen that causes fatal infections in patients with CF and immune deficiencies (2). However, treating infections attributable to *P. aeruginosa* is becoming increasingly difficult due to the widespread development of antibiotic resistance (2). Glycerol catabolism has been implicated in the adaptation of *P. aeruginosa* to the CF lung environment (4). In the present study, we identified the functions of glycerol metabolic genes, including *glpF*, *glpK*, *glpR*, and *glpD*, in *P. aeruginosa* PAO1. Notably, we established that, rather than glycerol, the glycerol catabolism regulator GlpR in




FIG 7 PA0562 and PA3172 contribute to G3P stress alleviation. (A and B) Log-phase growth rate (R) of $\Delta glpD$ complemented with empty vector pBBRMCS-5 (EV), pBBR-PA0562 (PA0562'), or pBBR-PA3172 (PA3172'). (C and D) Log-phase growth rate (R) of $\Delta glpD$ and $\Delta glpD\Delta PA0562\Delta PA3172$. All strains were grown with either 20 mM succinate (A and C) or 20 mM glucose (B and D) as the carbon source. The addition of 5 mM glycerol is indicated by the red columns. All data shown are the average values of three independent experiments \pm SD. Two-tailed P values were determined using unpaired t tests. **, $P < 0.01$; ****, $P < 0.0001$.

P. aeruginosa PAO1 uses G3P as its effector (Fig. S1D and E). We also investigated the synthesis, degradation, and transport mechanisms of G3P in *P. aeruginosa* PAO1. It was found that G3P is involved in maintaining the cellular homeostasis of *P. aeruginosa* PAO1 and that an accumulation of G3P leads to reductions in the growth of cells (Fig. 3; Fig. S2), production of several virulence factors, tolerance to oxidative stress, and resistance to kanamycin (Fig. 4; Fig. S3).

Although the specific mechanism by which the accumulation of G3P induces phenotypic alterations in *P. aeruginosa* PAO1 remains to be ascertained, we suspect that the growth inhibition caused by G3P stress may be associated with a remodeling of respiration and a reduction in ATP generation (Fig. 6). Furthermore, the observed decline in the twitching motility of *P. aeruginosa* PAO1 exposed to G3P stress (Fig. 4B) could be attributable to the repressed expression of type IVa pili biosynthesis genes (Table S1). A transcriptomic analysis further indicated that sulfur metabolism and antioxidant gene expression may also be influenced by G3P accumulation (Table S1), eventually resulting in a reduced tolerance to oxidative stress and a reduced resistance to kanamycin (Fig. 4D and E). Shuman et al. previously observed the upregulated expression of the *phz* operons in late-logarithmic-phase cultures of $\Delta glpD$ (45); however, a reduction in the production of pyocyanin was also reported in the $\Delta glpD$ mutants of *P. aeruginosa* strains FRD1 and PAO1 (46), which is concordant with our findings in the present study (Fig. 2A and Fig. 4A). We suspect that this reduction in pyocyanin production might be associated with a diversion of the metabolic flux of the key precursor, chorismate, to anthranilate degradation mediated via an upregulated expression of *antABC* (Fig. S4; Table S1). Pyocyanin is secreted in the stationary-phase of *P. aeruginosa* growth (47), and the downregulated *phz* in stationary-phase cells may also




FIG 8 Enzymatic characterization of PA0562 and PA3172 in *P. aeruginosa* PAO1. (A and B) The kinetic parameters of PA0562 (A) and PA3172 (B) were deduced from Michaelis-Menten regression curves. (C and D) Relative activities of PA0562 (C) and PA3172 (D) toward different substrates at 10 mM. The specific activity toward G3P was defined as 100%. GAP, 3-phosphoglycerate; 3PG, 3-phosphoglycerate; 2PG, 2-phosphoglycerate; G6P, glucose-6-phosphate; F6P, fructose-6-phosphate; 6PG, 6-phosphogluconate; R5P, ribose-5-phosphate; KDPG, 2-keto-3-deoxy-6-phosphogluconate. All data shown are the average values of three independent experiments \pm SD.

account for the reduced production of pyocyanin in the *glpD* mutant of *P. aeruginosa* (45).

The cellular toxicity caused by the accumulation of G3P appears to be a phenomenon shared by both prokaryotes and eukaryotes, as the negative effects of excess G3P on growth have been observed in *E. coli* (9, 48), *S. cerevisiae* (10), *C. glutamicum* (11), *M. tuberculosis* (49), and *C. elegans* (50). Moreover, HAD-like G3PPs that dephosphorylate G3P to glycerol and prevent an accumulation of G3P have been identified in *S. cerevisiae* (10), *C. glutamicum* (11), and *C. elegans* (50). In the present study, we identified and characterized the phosphatases PA0562 and PA3172 in *P. aeruginosa* PAO1, and the overexpression of PA0562 and PA3172 was found to alleviate G3P-induced growth inhibition, whereas the knockout of these two phosphatases potentiated the inhibitory effects of G3P (Fig. 7). G3PPs from glycerol-producing strains, such as *S. cerevisiae* (44) and *C. glutamicum* (11), exhibit high substrate specificity, which may be attributable to these microbes often having to contend with high G3P flux pressure. In contrast, we found that PA0562 and PA3172, like the HAD-like phosphatases in *E. coli* and *P. fluorescens* (42, 43), are characterized by relatively broad substrate spectra (Fig. 8C and D). The relaxed specificities of PA0562 and PA3172 imply that these phosphatases may play roles in other metabolic pathways or in the detoxification of other phosphorylated metabolites. For example, PA3172 has been found to catalyze the dephosphorylation of *N*-acetylmuramic acid-6-phosphate to *N*-acetylmuramic acid in the peptidoglycan recycling pathway (51).

Antibiotics are indispensable in the control of infections by pathogens. However, the overuse of antibiotics accelerates the evolution of multidrug-resistant bacteria (12). Accordingly, there is a constant need to identify novel drug targets in bacterial metabolic pathways and present new opportunities for the control of drug-resistant bacteria (52). For example, the catabolism of fatty acids is essential for the *in vivo* persistence

of *M. tuberculosis*. It has been demonstrated in a mouse infection model that the deletion of malate synthase, a key enzyme in the glyoxylate shunt pathway, reduces the infectivity of *M. tuberculosis* (16). The susceptibility of the malate synthase mutant of *M. tuberculosis* may be linked to the accumulation of glyoxylate, a toxic metabolite produced during the catabolism of fatty acids (16). Based on its crystal structure and its catalytic mechanism in *M. tuberculosis*, potent inhibitors of malate synthase have been developed for tuberculosis therapeutics (53). With respect to *P. aeruginosa*, it has been established that the adaptive evolution of *P. aeruginosa* in the host lung environment is associated with the metabolism of glycerol (4, 46). In the present study, we found that G3P stress that is induced by the deletion of GlpD reduces the growth and virulence factor production of *P. aeruginosa* PAO1 (Fig. 3 and Fig. 4). Thus, we believe that GlpD may also have potential therapeutic utility as a target for the control of *P. aeruginosa* infections. The structure of GlpD in *E. coli* has been resolved (54), and the GlpD in *P. aeruginosa* PAO1 displays 59% identity with the *E. coli* homolog and possesses consistent active sites. Thus, the inhibitors of GlpD could be designed and developed for the control of infections attributable to *P. aeruginosa*.

Bacterial antibiotic resistance has been shown to be closely correlated with physiological metabolism (13–15). In this context, metabolic modulations that enhance antibiotic efficiency have been used to manage infections induced by antibiotic-resistant bacteria. For example, exogenous glucose or alanine can increase the TCA flux, resulting in the stimulation of kanamycin uptake, which has been demonstrated to kill multi-drug-resistant bacteria both *in vitro* and in a mouse model of a urinary tract infection (55). Furthermore, it has been demonstrated that exposure to exogenous glutamine can increase the membrane permeability of many pathogens and can thereby promote the uptake of ampicillin to restore its antimicrobial activity (14). In the present study, we established that glycerol can greatly reduce the bactericidal concentration of kanamycin against $\Delta glpD$ (Fig. 4E) and that the reduced resistance phenotype is associated with a perturbation of G3P metabolism. Consequently, a GlpD inhibitor that influences G3P metabolism could potentially be administered in combination with antibiotics for a more effective control of difficult-to-treat *P. aeruginosa* infections.

In summary, we ascertained the functions of genes involved in G3P metabolism and demonstrated the importance of G3P homeostasis in *P. aeruginosa* PAO1. The accumulation of G3P reduced the virulence factor generation, inhibited the growth, and reduced the tolerance of *P. aeruginosa* PAO1 to oxidative and antibiotic stresses. Although further studies using infection models will be necessary to confirm whether GlpD plays an essential role *in vivo*, based on its involvement in the virulence phenotype, our findings provide evidence to indicate its potential utility as a drug target for the treatment of *P. aeruginosa* infections.

MATERIALS AND METHODS

Bacterial strains and culture conditions. The bacterial strains and plasmids used in this study are listed in Table S2. *P. aeruginosa* PAO1 and its derivatives were cultured in MSM (56) with different carbon sources at 180 rpm and 37°C. *E. coli* strains DH5 α and BL21(DE3) were cultured in LB medium at 180 rpm and 37°C. When necessary, antibiotics were added to the medium at the following concentrations, unless otherwise indicated: ampicillin, 100 $\mu\text{g mL}^{-1}$; gentamicin, 30 $\mu\text{g mL}^{-1}$; tetracycline, 40 $\mu\text{g mL}^{-1}$, respectively.

Gene knockout and complementation. The plasmids and primers used for the gene knockout and complementation are listed in Table S3. Mutants of *P. aeruginosa* PAO1 were constructed through the suicide plasmid pK18mobsacB-tet-mediated allelic exchange (57, 58). For the complementation of PA0562, the full-length of PA0562 was amplified from the genomic DNA of *P. aeruginosa* PAO1 using primers PA0562-F/PA0562-R, and the PCR product was cloned into the vector pBBR1MCS-5 (59) to get plasmid pBBR-PA0562. The recombinant plasmid pBBR-PA0562 was transformed into $\Delta glpD$ via electroporation. The correct transformants were selected on LB plates containing 45 $\mu\text{g mL}^{-1}$ gentamicin. $\Delta glpD$ complemented with pBBR-PA2067, pBBR-PA3172, and pBBR-glpD were obtained by using the same procedure.

Modeling growth. The growth of *P. aeruginosa* PAO1 and its derivatives in MSM with different carbon sources were monitored by using a BioScreen microbiology reader (BioScreen C LabSystems, Helsinki, Finland). The OD_{600nm} value of zero and different time points were defined as A₀ and A, respectively. Growth curves obtained by plotting the natural logarithm of A/A₀ versus time were fitted using the Gompertz (3 parameter) model (60). The log-phase growth rate R (h⁻¹) was calculated as the slope of the linear fit between the exponential-phase natural logarithm of A/A₀ and the time.

Expression and purification of proteins. The *glpR* gene was amplified from the genomic DNA of *P. aeruginosa* PAO1 using primers GlpR-F/GlpR-R and was cloned into the vector pETDuet-1. The recombinant plasmid pETDuet-*glpR* was introduced into *E. coli* BL21(DE3). The constructed strain was then grown to an OD_{600nm} of 0.6 to 0.8 in LB medium at 37°C and 180 rpm. Then, 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) was added to induce protein expression at 16°C and 160 rpm for 12 h. Cells were harvested and suspended in buffer A (50 mM Tris-HCl, 20 mM imidazole, and 500 mM NaCl, pH 7.4) containing 1 mM phenylmethanesulphonyl fluoride (PMSF) and 10% (vol/vol) glycerol. Then, the cells were lysed via sonication on ice, and the lysate was centrifuged at 12,000 × *g* for 40 min at 4°C. The supernatant was loaded onto a HisTrap HP column (5 mL) equilibrated with buffer A and eluted with buffer B (50 mM Tris-HCl, 1 M imidazole, and 500 mM NaCl, pH 7.4). The purified protein was analyzed by 13% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and was quantified using a Bradford protein assay kit (Sangon, China). PA0562 and PA3172 were expressed and purified by using the same procedure.

Electrophoretic mobility shift assay (EMSA). The DNA fragments of the *glpD* promoter, *glpFK* promoter, and control probe were amplified from the genomic DNA of *P. aeruginosa* PAO1 using primers P_{*glpD*}-F/P_{*glpD*}-R, P_{*glpFK*}-F/P_{*glpFK*}-R, and CP-F/CP-R (Table S3), respectively. The 20 μL reaction solution contained 3.5 nM target DNA fragments and control probe, 10 mM *sn*-glycerol 3-phosphate lithium salt (Sigma-Aldrich) or glycerol, and 500 nM purified GlpR in the binding buffer (pH 7.4, 10 mM Tris-HCl, 50 mM KCl, 0.5 mM EDTA, 10% [vol/vol] glycerol, 1 mM dithiothreitol [DTT]). The mixed solutions were incubated at 30°C for 30 min and loaded on 6% native polyacrylamide gels. Electrophoresis was performed at 170 V in 1× TBE buffer (pH 8.3) for 45 min. The gels were stained with SYBR green I (TaKaRa, China) for 20 min and then photographed using a G:BOX F3 gel documentation system (Syngene, USA).

Quantification of pyocyanin. Pyocyanin produced by *P. aeruginosa* PAO1 and its derivatives was quantified as previously described (61). Stationary-phase bacterial cultures (1.5 mL) were centrifuged at 13,000 × *g* for 5 min. Then, 1.25 mL of the supernatant was extracted with 0.75 mL chloroform. After centrifuging at 13,000 × *g* for 1 min, the upper water layer was removed, and the chloroform layer was mixed with 0.25 mL 0.2 M HCl and centrifuged again. Finally, 0.2 mL of the upper aqueous layer was transferred to a 96-well plate with a clear bottom, and the absorbance at 520 nm was measured by SpectraMax Plus 384 plate reader (Molecular Devices, USA). The final absorbance was normalized to the cell densities (OD_{600nm}).

Motility assays. For the twitching motilities of *P. aeruginosa* PAO1 and its derivatives, a single colony was stab inoculated to the bottom of LB or MSM plates containing 1% Difco bacto-agar by using a sterile toothpick. For the swimming motilities of *P. aeruginosa* PAO1 and its derivatives, a single colony was inoculated on the surface of MSM plates containing 0.3% Difco bacto-agar. After incubation at 37°C for 24 h, the zones of motility were measured and photographed using a G:BOX F3 gel documentation system (Syngene, USA).

Congo red binding assay. *P. aeruginosa* PAO1 and its derivatives were cultured overnight in LB and adjusted to an OD_{600nm} of 1 with normal saline. Then, 2 μL of the bacterial suspension was inoculated on the surface of LB agar plates containing 40 μg mL⁻¹ Congo red. The plates were photographed after incubation at 25°C for 4 days.

H₂O₂ susceptibility measurement. The overnight cultures of *P. aeruginosa* PAO1 and its derivatives were adjusted to an OD_{600nm} of 0.035 with normal saline and were inoculated into 50 mL of melted LB or MSM agar (1.6%) with medium cooling to the appropriate temperature. After solidification, sterile filter paper disks (approximately 6 mm) were placed in the center of the plate, and 10 μL of a 30% (wt/wt) H₂O₂ solution was instilled. After incubation at 37°C for 36 h, the zones of inhibition were measured and photographed using a G:BOX F3 gel documentation system (Syngene, USA).

Antibiotic resistance test. MSM agar (1.8%) plates with 20 mM succinate and increased concentrations of kanamycin were prepared and dried overnight. When necessary, 20 mM glycerol was also added to the MSM agar to induce G3P accumulation. The overnight cultures of *P. aeruginosa* PAO1 and its derivatives were washed and adjusted to an OD_{600nm} of 0.05 with normal saline. Then, 5 μL of the bacterial suspension was inoculated on the plates and cultured at 37°C for 4 days. The plates were photographed using a G:BOX F3 gel doc system (Syngene, USA).

Quantification of G3P. The concentration of G3P was determined by a commercial Glycerol 3-phosphate Colorimetric Assay Kit (MAK207, Sigma-Aldrich), following the manufacturer's instructions. *P. aeruginosa* PAO1 and Δ*glpD* were grown to an OD_{600nm} value of 1 in MSM containing 40 mM succinate or glucose as the carbon source. Then, 20 mM glycerol was added, and the strains were cultivated for 1.5 h. Bacterial cultures sampled before and after the glycerol treatment were subjected to G3P quantification. For the extracellular G3P assays, 15 μL of the culture medium supernatant was used for measurement. For the intracellular G3P assays, the cells of *P. aeruginosa* PAO1 and Δ*glpD* were centrifuged, washed, and adjusted to an OD_{600nm} of 7.5 in 200 μL of G3P assay buffer for cell lysis. After centrifugation at 13,000 × *g* for 5 min, 10 μL of the centrifugal supernatant was used for measurement. The content of G3P was calculated based on the standard curve and was normalized by the sample volume added to the detection system.

Transcriptional profiling and analysis. Δ*glpD* was cultured to an OD_{600nm} value of 1 in MSM containing 40 mM succinate as the carbon source. Then, 20 mM glycerol was added, and the strain was cultivated for 1.5 h. Cells of Δ*glpD* sampled before and after the glycerol treatment were quick-frozen in liquid nitrogen. Transcriptional profiling was performed by Shanghai Biozeron Biotechnology Co., Ltd. (China). Total RNA was extracted using the TRIzol Reagent (Invitrogen). RNA-seq strand-specific libraries were prepared following the TruSeq RNA sample preparation kit from Illumina (San Diego, CA). The libraries were sequenced using an Illumina HiSeq 2000. The clean reads were aligned to the reference genome of *P. aeruginosa* PAO1 using the Rockhopper software package. The differential expression analysis was conducted using edgeR.

Detection of ATP. The intracellular ATP of *P. aeruginosa* PAO1 and Δ gfpD was assessed by using the BacTiter-Glo Microbial Cell Viability Assay Kit (Promega), following the manufacturer's instructions. The sampling process was similar to that described in the G3P quantification methods. The bacterial cultures were centrifuged, washed, and resuspended to an OD_{600nm} of about 0.3. Subsequently, 100 μ L of the suspension was transferred into a black 96-well plate, mixed with an equal volume of the BacTiter-Glo Reagent, and incubated for 5 min at room temperature in the dark. The luminescence was detected by using an EnSight microplate reader (PerkinElmer, USA). The concentration of ATP was calculated based on the standard curve and was normalized by OD_{600nm}.

Enzymatic assay of G3PPs. The activities of PA0562 and PA3172 were assayed in 1 mL of reaction solution containing 0.2 mg mL⁻¹ of the purified enzyme, 5 mM MgCl₂, and increased concentrations of sn-glycerol 3-phosphate bis(cyclohexylammonium) salt (Sigma-Aldrich) in Tris-HCl (50 mM, pH 7.0). The samples were withdrawn and the released inorganic phosphate was analyzed as previously described (44). One unit (U) of G3PP activity was defined as the amount of enzyme that produced 1 μ mol of inorganic phosphate per minute.

Analytical methods. The concentrations of succinate and glycerol were determined using a high-performance liquid chromatography (HPLC) LC-20AT system (Shimadzu, Japan) that was equipped with an Aminex HPX-87H column (300 \times 7.8 mm, Bio-Rad, USA) and a refractive index detector. Briefly, the samples were boiled at 105°C for 15 min and centrifuged at 14,000 \times g for 15 min. The supernatants were analyzed by using 10 mM H₂SO₄ as the mobile phase with a flow rate of 0.4 mL min⁻¹. The concentration of glucose was determined by using a bio-analyzer (SBA-40D; Shandong Academy of Sciences).

Data availability. The raw data are publicly available through the NCBI SRA database (SRA accession number: PRJNA862672).

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

FIG S1, TIF file, 1.2 MB.

FIG S2, TIF file, 0.7 MB.

FIG S3, TIF file, 2.8 MB.

FIG S4, TIF file, 0.3 MB.

FIG S5, TIF file, 1.6 MB.

FIG S6, TIF file, 0.2 MB.

TABLE S1, DOC file, 1.3 MB.

TABLE S2, DOC file, 1.3 MB.

TABLE S3, DOC file, 1.3 MB.

ACKNOWLEDGMENTS

This work was supported by grants from the National Natural Science Foundation of China (31970056) and the Tianjin Synthetic Biotechnology Innovation Capacity Improvement Project (TSBICIP-KJGG-005). We also thank Xiangmei Ren from Core Facilities for Life and Environmental Sciences (State Key Laboratory of Microbial Technology, Shandong University) for assistance in the use of the BioScreen microbiology reader.

REFERENCES

1. Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warren P, Hickey MJ, Brinkman FS, Hufnagle WO, Kowalik DJ, Lagrou M, Garber RL, Goltry L, Tolentino E, Westbrock-Wadman S, Yuan Y, Brody LL, Coulter SN, Folger KR, Kas A, Larbig K, Lim R, Smith K, Spencer D, Wong GK, Wu Z, Paulsen IT, Reizer J, Saier MH, Hancock RE, Lory S, Olson MV. 2000. Complete genome sequence of *Pseudomonas aeruginosa* PAO1, an opportunistic pathogen. *Nature* 406:959–964. <https://doi.org/10.1038/35023079>.
2. Rossi E, La Rosa R, Bartell JA, Marvig RL, Haagensen JAJ, Sommer LM, Molin S, Johansen HK. 2021. *Pseudomonas aeruginosa* adaptation and evolution in patients with cystic fibrosis. *Nat Rev Microbiol* 19:331–342. <https://doi.org/10.1038/s41579-020-00477-5>.
3. Jurado-Martín I, Sainz-Mejías M, McClean S. 2021. *Pseudomonas aeruginosa*: an audacious pathogen with an adaptable arsenal of virulence factors. *Int J Mol Sci* 22:3128. <https://doi.org/10.3390/ijms22063128>.
4. Son MS, Matthews WJ, Kang Y, Nguyen DT, Hoang TT. 2007. *In vivo* evidence of *Pseudomonas aeruginosa* nutrient acquisition and pathogenesis in the lungs of cystic fibrosis patients. *Infect Immun* 75:5313–5324. <https://doi.org/10.1128/IAI.01807-06>.
5. Pobleste-Castro I, Wittmann C, Nickel PI. 2020. Biochemistry, genetics and biotechnology of glycerol utilization in *Pseudomonas* species. *Microb Biotechnol* 13:32–53. <https://doi.org/10.1111/1751-7915.13400>.
6. Nickel PI, Kim J, de Lorenzo V. 2014. Metabolic and regulatory rearrangements underlying glycerol metabolism in *Pseudomonas putida* KT2440. *Environ Microbiol* 16:239–254. <https://doi.org/10.1111/1462-2920.12224>.
7. Cronan JE. 2003. Bacterial membrane lipids: where do we stand? *Annu Rev Microbiol* 57:203–224. <https://doi.org/10.1146/annurev.micro.57.030502.090851>.
8. Alvarez HM. 2016. Triacylglycerol and wax ester-accumulating machinery in prokaryotes. *Biochimie* 120:28–39. <https://doi.org/10.1016/j.biochi.2015.08.016>.
9. Cozzarelli NR, Koch JP, Hayashi S, Lin EC. 1965. Growth stasis by accumulated L- α -glycerophosphate in *Escherichia coli*. *J Bacteriol* 90:1325–1329. <https://doi.org/10.1128/jb.90.5.1325-1329.1965>.
10. Pählman AK, Granath K, Ansell R, Hohmann S, Adler L. 2001. The yeast glycerol 3-phosphatases Gpp1p and Gpp2p are required for glycerol biosynthesis and differentially involved in the cellular responses to osmotic, anaerobic, and oxidative stress. *J Biol Chem* 276:3555–3563. <https://doi.org/10.1074/jbc.M007164200>.
11. Lindner SN, Meiswinkel TM, Panhorst M, Youn JW, Wiefel L, Wendisch VF. 2012. Glycerol-3-phosphatase of *Corynebacterium glutamicum*. *J Biotechnol* 159:216–224. <https://doi.org/10.1016/j.jbiotec.2012.02.003>.

12. Huemer M, Mairpady SS, Brugger SD, Zinkernagel AS. 2020. Antibiotic resistance and persistence—implications for human health and treatment perspectives. *EMBO Rep* 21:e51034. <https://doi.org/10.15252/embr.202051034>.
13. Stokes JM, Lopatkin AJ, Lobritz MA, Collins JJ. 2019. Bacterial metabolism and antibiotic efficacy. *Cell Metab* 30:251–259. <https://doi.org/10.1016/j.cmet.2019.06.009>.
14. Zhao XL, Chen ZG, Yang TC, Jiang M, Wang J, Cheng ZX, Yang MJ, Zhu JX, Zhang TT, Li H, Peng B, Peng XX. 2021. Glutamine promotes antibiotic uptake to kill multidrug-resistant uropathogenic bacteria. *Sci Transl Med* 13:eabj0716. <https://doi.org/10.1126/scitranslmed.abj0716>.
15. Lopatkin AJ, Bening SC, Manson AL, Stokes JM, Kohanski MA, Badran AH, Earl AM, Cheney NJ, Yang JH, Collins JJ. 2021. Clinically relevant mutations in core metabolic genes confer antibiotic resistance. *Science* 371:eaba0862. <https://doi.org/10.1126/science.aba0862>.
16. Puckett S, Trujillo C, Wang Z, Eoh H, loerger TR, Krieger I, Sacchetti J, Schnappinger D, Rhee KY, Ehrst S. 2017. Glyoxylate detoxification is an essential function of malate synthase required for carbon assimilation in *Mycobacterium tuberculosis*. *Proc Natl Acad Sci U S A* 114:E2225–E2232. <https://doi.org/10.1073/pnas.1617655114>.
17. Keohane CE, Steele AD, Fetzter C, Khowsathit J, Van Tyne D, Moynié L, Gilmore MS, Karanickolas J, Sieber SA, Wuest WM. 2018. Promysalin elicits species-selective inhibition of *Pseudomonas aeruginosa* by targeting succinate dehydrogenase. *J Am Chem Soc* 140:1774–1782. <https://doi.org/10.1021/jacs.7b11212>.
18. Schweizer HP, Jump R, Po C. 1997. Structure and gene-polypeptide relationships of the region encoding glycerol diffusion facilitator (*glpF*) and glycerol kinase (*glpK*) of *Pseudomonas aeruginosa*. *Microbiology* 143:1287–1297. <https://doi.org/10.1099/00221287-143-4-1287>.
19. Schweizer HP, Po C. 1996. Regulation of glycerol metabolism in *Pseudomonas aeruginosa*: characterization of the *glpR* repressor gene. *J Bacteriol* 178:5215–5221. <https://doi.org/10.1128/jb.178.17.5215-5221.1996>.
20. Schweizer HP, Po C. 1994. Cloning and nucleotide sequence of the *glpD* gene encoding sn-glycerol-3-phosphate dehydrogenase of *Pseudomonas aeruginosa*. *J Bacteriol* 176:2184–2193. <https://doi.org/10.1128/jb.176.8.2184-2193.1994>.
21. Nikel PI, Romero-Campero FJ, Zeidman JA, Goñi-Moreno Á, de Lorenzo V. 2015. The glycerol-dependent metabolic persistence of *Pseudomonas putida* KT2440 reflects the regulatory logic of the *GlpR* repressor. *mBio* 6:e00340-15. <https://doi.org/10.1128/mBio.00340-15>.
22. Kito M, Pizer LI. 1969. Purification and regulatory properties of the biosynthetic L-glycerol 3-phosphate dehydrogenase from *Escherichia coli*. *J Biol Chem* 244:3316–3323. [https://doi.org/10.1016/S0021-9258\(18\)93129-7](https://doi.org/10.1016/S0021-9258(18)93129-7).
23. Edgar JR, Bell RM. 1978. Biosynthesis in *Escherichia coli* of sn-glycerol 3-phosphate, a precursor of phospholipid. *J Biol Chem* 253:6348–6353. [https://doi.org/10.1016/S0021-9258\(19\)46940-8](https://doi.org/10.1016/S0021-9258(19)46940-8).
24. Castañeda-García A, Rodríguez-Rojas A, Guelfo JR, Blázquez J. 2009. The glycerol-3-phosphate permease *GlpT* is the only fosfomycin transporter in *Pseudomonas aeruginosa*. *J Bacteriol* 191:6968–6974. <https://doi.org/10.1128/JB.00748-09>.
25. Mattick JS. 2002. Type IV pili and twitching motility. *Annu Rev Microbiol* 56:289–314. <https://doi.org/10.1146/annurev.micro.56.012302.160938>.
26. Colvin KM, Gordon VD, Murakami K, Borlee BR, Wozniak DJ, Wong GC, Parsek MR. 2011. The *Pel* polysaccharide can serve a structural and protective role in the biofilm matrix of *Pseudomonas aeruginosa*. *PLoS Pathog* 7:e1001264. <https://doi.org/10.1371/journal.ppat.1001264>.
27. Ueda A, Wood TK. 2009. Connecting quorum sensing, c-di-GMP, *Pel* polysaccharide, and biofilm formation in *Pseudomonas aeruginosa* through tyrosine phosphatase *TpbA* (PA3885). *PLoS Pathog* 5:e1000483. <https://doi.org/10.1371/journal.ppat.1000483>.
28. Da Cruz Nizer WS, Inkovskiy V, Versey Z, Strempele N, Cassol E, Overhage J. 2021. Oxidative stress response in *Pseudomonas aeruginosa*. *Pathogens* 10:1187. <https://doi.org/10.3390/pathogens10091187>.
29. Burrows LL. 2012. *Pseudomonas aeruginosa* twitching motility: type IV pili in action. *Annu Rev Microbiol* 66:493–520. <https://doi.org/10.1146/annurev-micro-092611-150055>.
30. de Bentzmann S, Aurouze M, Ball G, Filloux A. 2006. *FppA*, a novel *Pseudomonas aeruginosa* prepilin peptidase involved in assembly of type IV pili. *J Bacteriol* 188:4851–4860. <https://doi.org/10.1128/JB.00345-06>.
31. Wei Q, Minh PN, Dötsch A, Hildebrand F, Panmanee W, Elfarash A, Schulz S, Plaisance S, Charlier D, Hassett D, Häussler S, Cornelis P. 2012. Global regulation of gene expression by *OxyR* in an important human opportunistic pathogen. *Nucleic Acids Res* 40:4320–4333. <https://doi.org/10.1093/nar/gks017>.
32. Hare NJ, Scott NE, Shin EH, Connolly AM, Larsen MR, Palmisano G, Cordwell SJ. 2011. Proteomics of the oxidative stress response induced by hydrogen peroxide and paraquat reveals a novel AhpC-like protein in *Pseudomonas aeruginosa*. *Proteomics* 11:3056–3069. <https://doi.org/10.1002/pmic.201000807>.
33. Kertesz MA. 2000. Riding the sulfur cycle—metabolism of sulfonates and sulfate esters in gram-negative bacteria. *FEMS Microbiol Rev* 24:135–175. [https://doi.org/10.1016/S0168-6445\(99\)00033-9](https://doi.org/10.1016/S0168-6445(99)00033-9).
34. Shatalin K, Shatalina E, Mironov A, Nudler E. 2011. H₂S: a universal defense against antibiotics in bacteria. *Science* 334:986–990. <https://doi.org/10.1126/science.1209855>.
35. Romsang A, Duang-Nkern J, Leesukon P, Saninjuk K, Vattanaviboon P, Mongkolsuk S. 2014. The iron-sulphur cluster biosynthesis regulator *IscR* contributes to iron homeostasis and resistance to oxidants in *Pseudomonas aeruginosa*. *PLoS One* 9:e86763. <https://doi.org/10.1371/journal.pone.0086763>.
36. Pierson LS, Pierson EA. 2010. Metabolism and function of phenazines in bacteria: impacts on the behavior of bacteria in the environment and biotechnological processes. *Appl Microbiol Biotechnol* 86:1659–1670. <https://doi.org/10.1007/s00253-010-2509-3>.
37. Campilongo R, Fung RKY, Little RH, Grenga L, Trampari E, Pepe S, Chandra G, Stevenson CEM, Roncarati D, Malone JG. 2017. One ligand, two regulators and three binding sites: how KDPG controls primary carbon metabolism in *Pseudomonas*. *PLoS Genet* 13:e1006839. <https://doi.org/10.1371/journal.pgen.1006839>.
38. Rae JL, Cutfield JF, Lamont IL. 1997. Sequences and expression of pyruvate dehydrogenase genes from *Pseudomonas aeruginosa*. *J Bacteriol* 179:3561–3571. <https://doi.org/10.1128/jb.179.11.3561-3571.1997>.
39. Arai H, Kawakami T, Osamura T, Hirai T, Sakai Y, Ishii M. 2014. Enzymatic characterization and *in vivo* function of five terminal oxidases in *Pseudomonas aeruginosa*. *J Bacteriol* 196:4206–4215. <https://doi.org/10.1128/JB.02176-14>.
40. Schober M, Jahn D. 2010. Anaerobic physiology of *Pseudomonas aeruginosa* in the cystic fibrosis lung. *Int J Med Microbiol* 300:549–556. <https://doi.org/10.1016/j.ijmm.2010.08.007>.
41. Koonin EV, Tatusov RL. 1994. Computer analysis of bacterial haloacid dehalogenases defines a large superfamily of hydrolases with diverse specificity. *J Mol Biol* 244:125–132. <https://doi.org/10.1006/jmbi.1994.1711>.
42. Kuznetsova E, Proudfoot M, Gonzalez CF, Brown G, Omelchenko MV, Borozan I, Carmel L, Wolf YI, Mori H, Savchenko AV, Arrowsmith CH, Koonin EV, Edwards AM, Yakunin AF. 2006. Genome-wide analysis of substrate specificities of the *Escherichia coli* haloacid dehalogenase-like phosphatase family. *J Biol Chem* 281:36149–36161. <https://doi.org/10.1074/jbc.M605449200>.
43. Maleki S, Hrudikova R, Zotchev SB, Ertesvåg H. 2017. Identification of a new phosphatase enzyme potentially involved in the sugar phosphate stress response in *Pseudomonas fluorescens*. *Appl Environ Microbiol* 83:e02361-16. <https://doi.org/10.1128/AEM.02361-16>.
44. Norbeck J, Pählman AK, Akhtar N, Blomberg A, Adler L. 1996. Purification and characterization of two isoenzymes of DL-glycerol-3-phosphatase from *Saccharomyces cerevisiae*. *J Biol Chem* 271:13875–13881. <https://doi.org/10.1074/jbc.271.23.13875>.
45. Shuman J, Giles TX, Carroll L, Tabata K, Powers A, Suh SJ, Silo-Suh L. 2018. Transcriptome analysis of a *Pseudomonas aeruginosa* sn-glycerol-3-phosphate dehydrogenase mutant reveals a disruption in bioenergetics. *Microbiology (Reading)* 164:551–562. <https://doi.org/10.1099/mic.0.000646>.
46. Daniels JB, Scofield J, Woolnough JL, Silo-Suh L. 2014. Impact of glycerol-3-phosphate dehydrogenase on virulence factor production by *Pseudomonas aeruginosa*. *Can J Microbiol* 60:857–863. <https://doi.org/10.1139/cjm-2014-0485>.
47. Dietrich LE, Price-Whelan A, Petersen A, Whiteley M, Newman DK. 2006. The phenazine pyocyanin is a terminal signalling factor in the quorum sensing network of *Pseudomonas aeruginosa*. *Mol Microbiol* 61:1308–1321. <https://doi.org/10.1111/j.1365-2958.2006.05306.x>.
48. Hennen PE, Carter HB, Nunn WD. 1978. Changes in macromolecular synthesis and nucleoside triphosphate levels during glycerol-induced growth stasis of *Escherichia coli*. *J Bacteriol* 136:929–935. <https://doi.org/10.1128/jb.136.3.929-935.1978>.
49. Pethe K, Sequeira PC, Agarwalla S, Rhee K, Kuhen K, Phong WY, Patel V, Beer D, Walker JR, Duraiswamy J, Jiricek J, Keller TH, Chatterjee A, Tan MP, Ujjini M, Rao SPS, Camacho L, Bifani P, Mak PA, Ma I, Barnes SW, Chen Z, Plouffe D, Thayalan P, Ng SH, Au M, Lee BH, Tan BH, Ravindra S, Nanjundappa M, Lin X, Goh A, Lakshminarayana SB, Shoen C, Cynamon M, Kreiswirth B, Dartois V, Peters EC, Glynn R, Brenner S, Dick T. 2010. A chemical genetic screen in *Mycobacterium tuberculosis* identifies carbon-

- source-dependent growth inhibitors devoid of *in vivo* efficacy. *Nat Commun* 1:57. <https://doi.org/10.1038/ncomms1060>.
50. Possik E, Schmitt C, Al-Mass A, Bai Y, Côté L, Morin J, Erb H, Oppong A, Kahloan W, Parker JA, Madiraju SRM, Prentki M. 2022. Phosphoglycolate phosphatase homologs act as glycerol-3-phosphate phosphatase to control stress and healthspan in *C. elegans*. *Nat Commun* 13:177. <https://doi.org/10.1038/s41467-021-27803-6>.
 51. Fumeaux C, Bernhardt TG. 2017. Identification of MupP as a new peptidoglycan recycling factor and antibiotic resistance determinant in *Pseudomonas aeruginosa*. *mBio* 8:e00102-17. <https://doi.org/10.1128/mBio.00102-17>.
 52. Shapiro JA, Kaplan AR, Wuest WM. 2019. From general to specific: can *Pseudomonas* primary metabolism be exploited for narrow-spectrum antibiotics? *Chembiochem* 20:34–39. <https://doi.org/10.1002/cbic.201800383>.
 53. Krieger IV, Freundlich JS, Gawandi VB, Roberts JP, Gawandi VB, Sun Q, Owen JL, Fraile MT, Huss SI, Lavandera JL, loerger TR, Sacchettini JC. 2012. Structure-guided discovery of phenyl-diketo acids as potent inhibitors of *M. tuberculosis* malate synthase. *Chem Biol* 19:1556–1567. <https://doi.org/10.1016/j.chembiol.2012.09.018>.
 54. Yeh JI, Chinte U, Du S. 2008. Structure of glycerol-3-phosphate dehydrogenase, an essential monotopic membrane enzyme involved in respiration and metabolism. *Proc Natl Acad Sci U S A* 105:3280–3285. <https://doi.org/10.1073/pnas.0712331105>.
 55. Peng B, Su YB, Li H, Han Y, Guo C, Tian YM, Peng XX. 2015. Exogenous alanine and/or glucose plus kanamycin kills antibiotic-resistant bacteria. *Cell Metab* 21:249–262. <https://doi.org/10.1016/j.cmet.2015.01.008>.
 56. Baginsky ML, Rodwell VW. 1966. Metabolism of pipercolic acid in a *Pseudomonas* species IV. Electron transport particle of *Pseudomonas putida*. *J Bacteriol* 92:424–432. <https://doi.org/10.1128/jb.92.2.424-432.1966>.
 57. Schäfer A, Tauch A, Jäger W, Kalinowski J, Thierbach G, Pühler A. 1994. Small mobilizable multi-purpose cloning vectors derived from the *Escherichia coli* plasmids pK18 and pK19: selection of defined deletions in the chromosome of *Corynebacterium glutamicum*. *Gene* 145:69–73. [https://doi.org/10.1016/0378-1119\(94\)90324-7](https://doi.org/10.1016/0378-1119(94)90324-7).
 58. Xiao D, Zhang W, Guo X, Liu Y, Hu C, Guo S, Kang Z, Xu X, Ma C, Gao C, Xu P. 2021. A D-2-hydroxyglutarate biosensor based on specific transcriptional regulator DhdR. *Nat Commun* 12:7108. <https://doi.org/10.1038/s41467-021-27357-7>.
 59. Kovach ME, Elzer PH, Hill DS, Robertson GT, Farris MA, Roop RM, 2nd, Peterson KM. 1995. Four new derivatives of the broad-host-range cloning vector pBBR1MCS, carrying different antibiotic-resistance cassettes. *Gene* 166:175–176. [https://doi.org/10.1016/0378-1119\(95\)00584-1](https://doi.org/10.1016/0378-1119(95)00584-1).
 60. Zwietering MH, Jongenburger I, Rombouts FM, van 't Riet K. 1990. Modeling of the bacterial growth curve. *Appl Environ Microbiol* 56:1875–1881. <https://doi.org/10.1128/aem.56.6.1875-1881.1990>.
 61. Essar DW, Eberly L, Hadero A, Crawford IP. 1990. Identification and characterization of genes for a second anthranilate synthase in *Pseudomonas aeruginosa*: interchangeability of the two anthranilate synthases and evolutionary implications. *J Bacteriol* 172:884–900. <https://doi.org/10.1128/jb.172.2.884-900.1990>.